Missense mutations may affect proteostasis by destabilizing or over-stabilizing protein complexes and changing the pathway flux. Predicting the effects of stabilizing mutations on protein-protein interactions is notoriously difficult because existing experimental sets are skewed toward mutations reducing protein-protein binding affinity and many computational methods fail to correctly evaluate their effects. To address this issue, we developed a method MutaBind2, which estimates the impacts of single as well as multiple mutations on protein-protein interactions. MutaBind2 employs only seven features, and the most important of them describe interactions of proteins with the solvent, evolutionary conservation of the site, and thermodynamic stability of the complex and each monomer. This approach shows a distinct improvement especially in evaluating the effects of mutations increasing binding affinity. MutaBind2 can be used for finding disease driver mutations, designing stable protein complexes, and discovering new protein-protein interaction inhibitors.
INTRODUCTION
Protein-protein interactions mediate many biological processes, and missense mutations may affect protein interactions and interaction networks leading to dysfunctional proteins and their complexes, pathway dysregulation, and potentially to diseases (Teng et al., 2009; Nishi et al., 2013; Creixell et al., 2015; Tee et al., 2019) . Indeed, several recent studies systematically characterized thousands of disease mutations and found that many of them were located on protein-binding interfaces and induced macromolecular interaction perturbations, whereas neutral variants retained most interactions (Nishi et al., 2013; Teng et al., 2009; Creixell et al., 2015; Sahni et al., 2015; Wang et al., 2012; Cukuroglu et al., 2014; Tan et al., 2019; Ozdemir et al., 2018) . However, not all mutations have severe damaging impacts, and the majority of mutations produce rather subtle effects with unclear clinical significance. Quantification of these effects on specific protein-protein interactions requires assessing the changes in binding affinity induced by mutations. These effects can be quite accurately measured by lowthroughput experiments. However, large-scale rapid experimental assays that would allow the assessment of thousands of variants are still limited. The development of reliable computational approaches to predict the effects of missense mutations on protein complexes would enable the prioritization of functionally disrupting mutations and provide a basis for understanding the molecular mechanisms of their impacts. Several computational approaches have been proposed so far to calculate the changes in binding affinity by mutations (Li et al., 2014 (Li et al., , 2016b Dehouck et al., 2013; Petukh et al., 2015 Petukh et al., , 2016 Kruger and Gohlke, 2010; Pires et al., 2014; Xiong et al., 2017; Brender and Zhang, 2015; Zhao et al., 2014; Geng et al., 2019; Jemimah et al., 2019) . In the past we developed two methods to address this pressing need. The first method used the modified MM/PBSA (Molecular Mechanics PoissonÀBoltzmann Surface Area) approach and structure optimization protocol with an explicit solvent model (Li et al., 2014) . Later we came up with another method, MutaBind (Li et al., 2016b) . MutaBind was characterized by higher prediction accuracy and speed, making it possible to implement it as a web server, which has been used to quantify the impacts of mutations in a wide range of protein complexes (https://mutabind.org/v1). For instance, it was successfully applied to assess the effects of cancer mutations on binding between CBL ubiquitin ligase and E2 conjugating enzyme where computationally predicted binding affinity changes were compared with the experiments using cancer and non-cancer cell lines (Li et al., 2016a) .
The functional effects of mutations decreasing binding affinity are better understood compared with the effects of mutations increasing binding affinity. However, the latter may also have important consequences leading to disruption of proteostasis by over-stabilizing transient protein complexes (Nishi et al., 2013; Stefl et al., 2013; Rutten et al., 2018; Shoichet et al., 1995; Nagatani et al., 2007; Witham et al., 2011; Jubb et al., 2016) and changing the pathway flux. Critically, existing computational methods perform much better for mutations decreasing than for mutations increasing binding affinity. Several studies tried to determine factors contributing to this bias by comparing the methods' performance using experimental data on changes of protein stability (Usmanova et al., 2018; Montanucci et al., 2018; Pucci et al., 2018) . These studies concluded that all computational methods produced predictions that were immensely skewed toward higher accuracy for mutations decreasing binding affinity and the amplitude of this bias increased with the number of introduced mutations in a protein (Usmanova et al., 2018) . There are several reasons for such predisposition of proteins toward mutations with decreasing effects: proteins and their binding interfaces tend to be optimized in evolution with regard to their stability; the existing experimental sets are enriched with mutations that decrease binding and the methodologies of training procedures employed by many computational methods rely on these experimental sets. Correcting for such bias in performance is demanding as it requires developing new energy functions and enriching the datasets with mutations increasing binding affinity either by using additional experimental data or by calculating the effects of reverse mutations and modeling their mutant structures.
To address this issue, we developed a new method, MutaBind2, with significantly improved performance (https://mutabind.org/). MutaBind2 uses a new minimization protocol and scoring function composed of seven terms. In addition to single mutations, it can predict the effects of multiple mutations on protein binding affinity. MutaBind2 can be applied to a large number of tasks, including, but not limited to, finding disease driver mutations and understanding their molecular mechanisms, assessing the effects of sequence variants on protein fitness, structural modeling of mutant complexes, and designing protein interaction inhibitors (Goncearenco et al., 2017) .
RESULTS AND DISCUSSION
By developing a new version of MutaBind2 we tried to achieve the following goals: (1) to improve the overall performance, especially for mutations increasing binding affinity; (2) to avoid overfitting; and (3) to allow for multiple mutations predictions. To do this, first we designed a scoring function with seven terms instead of 10 used in the previous MutaBind version (detailed in Supplemental Information, Transparent Methods). Second, we trained our models on a much larger dataset from SKEMPI2, which encompassed 1.7 times more mutations and 3.3 times more complexes compared with SKEMPI used for training of MutaBind. Third, to enrich the existing dataset with mutations increasing binding affinity and to build a more balanced training dataset, we produced structural models of complexes with reverse mutations and estimated the corresponding values of each term of the scoring function. Finally, we added a new functionality of predicting the effects of multiple mutations (up to 10 mutations) on binding affinity to account for possible cooperative and epistatic effects. Table S1 .
Evaluating the Performance of MutaBind2 Using Cross-Validation
Avoiding overfitting is one of our major concerns while developing a computational method that should make predictions with high accuracy for diverse sets of single or multiple mutations. Overfitting of model parameters may occur while minimizing the mean square deviations of predicted from experimental values in the training set, which could indicate the loss of generalization in the model (Dehouck et al., 2013) . To overcome this issue, a cross-validation can be applied, which allows to estimate the future performance of the method on previously unseen data. Five types of cross-validation were performed in our study (explained in more detail in the Methods section). Figure 1 shows the Pearson correlation coefficients between experimental and calculated DDG of the first three types of cross-validation procedures. The correlation coefficients of each cross-validation round exceed 0.80 for ''CV1'' and ''CV2'' and about 0.70 for ''CV3'' cross-validation for both single and multiple mutations.
The Pearson correlation coefficient between experimental and computed DDG values using the ''leave-onecomplex-out'' (''CV4'') procedure reaches 0.76 for single mutations and 0.74 for multiple mutations (Table 1 and Figure 2 ). In addition, we performed a validation by leaving one binding site out of the training set (''CV5'' cross-validation). According to this validation, the model was parameterized and tested using completely different non-overlapping sets of binding sites. Nevertheless, the correlation coefficient remained statistically significant, being equal to 0.69 for single mutations and 0.71 for multiple mutations (Table 1 and Figure S4D) . From the evaluation of the performance of MutaBind2 using cross-validation, we can conclude that the MutaBind2 for single mutations significantly outperforms the previous version of MutaBind, which had R = 0.68 and R = 0.57 for ''CV4' ' and ''CV5,'' respectively (Li et al., 2016b ) (see Table 1 for RMSE values).
To better understand MutaBind2's limitations and strengths, we analyzed 5% and 1% outliers and evaluated the performance after removing outliers using leave-one-complex-out validation (CV4) on S4191. Studentized residuals are used in detecting outliers. Figure S11A shows that the performance is improved significantly after removing 5% outliers. Moreover, we found that the outliers are more likely to appear in complexes with higher protein-protein binding affinity and at the mutated sites with higher number of hydrogen bonds ( Figure S11B ). Consistent with the observation of Pires et al. (Pires et al., 2016) , the outliers usually correspond to those mutations with extreme experimental values (highly decreasing/increasing binding affinity), and MutaBind2 could correctly classify them as either increasing or decreasing binding affinity (Figures S11C and S11D).
Validation of MutaBind2 on Independent Test Sets
To check if enriching the training set with mutations increasing binding affinity improved the performance, we constructed an independent ''unseen'' test set consisting of complexes and mutations that were present in SKEMPI2 but were absent from SKEMPI (S1748 set). The original version of MutaBind, which was trained on binding affinity changes dataset from SKEMPI (referred to as the ''Skempi'' set), yielded a Pearson correlation coefficient of R = 0.44 between predicted and experimentally determined values for mutations decreasing binding affinity on an independent S1748 set, whereas it did not yield statistically significantly predictions for mutations increasing binding affinity (Table 1 and Figure S4A ). However, after applying a model trained on the SKEMPI set enriched with mutations increasing binding affinity (''Skempi + Reverse'' set) using MutaBind2 features and protocol, the performance on an independent S1748 set improved considerably (the correlation coefficient increased from 0.38 to 0.63, and root-mean-square error decreased from 1.51 to 1.25 kcal mol À1 ). Moreover, predictions for mutations increasing binding affinity were significantly improved without compromising the accuracy for predicting mutations decreasing binding affinity (Table 1) .
For single mutations, we also compared MutaBind2 with four other methods, BeAtMuSiC (Dehouck et al., 2013) , FoldX (Guerois et al., 2002 ), iSEE (Geng et al., 2019 , and mCSM-PPI2 . BeAt-MuSiC is a machine learning method, which uses a combination of different statistical potentials to predict DDG values and is parameterized on mutations from SKEMPI. FoldX uses an empirical energy function, which is parametrized on experimental changes of unfolding free energy. iSEE is parameterized on the SKEMPI set and uses several dozens of interface, structure, evolution, and energy-based features. iSEE is not available as a server or a standalone version, so it could not be applied to the S1748 set. mCSM-PPI2 uses several dozens of features such as graph-based signatures, evolutionary conservation, and interaction energy between two partners calculated from FoldX and also incorporates features derived from reverse mutations. It has been trained on 8,338 mutations from the SKEMPI2 dataset, which includes almost all mutations from the MutaBind2 training dataset S4191.
For comparison with iSEE, we used the S487 dataset obtained from the iSEE article (Geng et al., 2019) where the MutaBind2 model was retrained after removing S487 from the S4191 training set. As can be seen in Table 2 , the MutaBind2 model parameterized on this training set shows the best performance on S487 compared with other methods (more comparisons can be found in Table S5 ). We did not have an independent set for comparing the predictions between MutaBind2 and mCSM-PPI2, therefore we used the same training protocol and retrained MutaBind2 on the dataset of S8338 (a training dataset of mCSM-PPI2), even though our feature selection was not based on this dataset. We obtained comparable correlation coefficients with mCSM-PPI2 using the CV4 and CV5 cross-validations (Table 2) , which were slightly lower than results reported for the original MutaBind2 model on the S4191 (Table 1) . Additional comparisons with mCSM-PPI2 are shown in Table S6 , which points to a slightly Table S1 .
better performance for MutaBind2 in terms of the slope of the regression line indicating that predicted and experimental values are on the same scale.
Recently the impacts of 2,009 missense mutations across 2,185 human protein-protein interactions (4,797 mutation-interaction pairs) were measured by yeast two hybrid experiments (Fragoza et al., 2019) , and 903 mutations were identified as interaction-disruptive mutations. A mutation was defined as disruptive if it damaged one or more protein-protein interactions and was defined as non-disruptive otherwise. Among 4,797 mutation-interaction pairs, 451 mutations, including 147 interaction disruptive mutations, could be mapped on corresponding protein-protein complexes with the known 3D structures. Then we calculated binding affinity changes for these mutations using different methods. Figures 3 and S5 show excellent performance of MutaBind and MutaBind2 in distinguishing interaction-disruptive from other mutations.
Prediction of Mutations Highly Decreasing and Increasing Binding Affinity
The previous version, MutaBind, could predict single mutations highly decreasing binding affinity relatively well but failed to annotate mutations highly increasing affinity. Table 3 and Figure S6 demonstrate the high performance of MutaBind2 in predicting mutations highly decreasing and highly increasing binding affinity (see Methods for details). MutaBind2 further improves the performance for both interfacial and non-interfacial mutations compared with the previous version and outperforms other methods on the S1748 set (Figure S7) . We subdivided complexes with multiple mutations into different categories based on the number of mutations and the number of mutated chains involved (see Table S9 for more details). We found that MutaBind2 performed well for almost all categories; the worst performance was observed for three or more mutations introduced on the same chain (R = 0.61 in CV4 validation), and the best performance was achieved for double mutations on multiple chains (R = 0.85 in CV4 validation).
Next we would like to elucidate the main differences between predictors like BeAtMuSiC, iSEE, and mCSM-PPI2 and methods like FoldX, MutaBind, and MutaBind2. The first group of methods uses powerful machine learning approaches with several dozens of features to calculate the changes in binding affinity and does not provide contribution of each feature for each mutation. On the other hand, methods like FoldX, MutaBind, and Muta-Bind2 use very few interpretable energy terms and perform structure optimization and energy calculations. This allows the construction of actual molecular models of mutant structures and to evaluate changes in binding affinity for these mutants, potentially accounting for structural changes that cannot be captured by machine learning methods. The molecular models of mutants have been used extensively by researchers to understand the molecular mechanisms of disease mutations, to design drugs, to identify drug targets, to predict driver mutations, and to decipher the mechanisms of drug-resistant mutations ( Figure S8 ). Importantly, MutaBind and MutaBind2, unlike other methods mentioned earlier, estimate interactions of a protein with the solvent, which is one of the most important terms together with the site evolutionary conservation and thermodynamic stability of a protein complex and each binding partner (Table S2 ). In addition, FoldX and MutaBind2 provide predictions and structural models for multiple mutations introduced at the same time in a protein complex.
Online Web Server
MutaBind2 is available at https://mutabind.org/v2. The main requirement of the webserver is the availability of the 3D structure of a protein-protein complex, which can be provided by the Protein DataBank accession or by a file with the coordinates uploaded by the researcher. In either case, the structure file should contain at least two protein chains. In the next step two interaction partners should be defined. It is possible to assign one chain or multiple chains to either ''Partner 1'' or ''Partner 2,'' and only assigned chains will be considered during the calculation. If the interface size between assigned partners is smaller than 100 Å 2 , an error message is displayed. The interface size is calculated as a difference between the solvent-accessible surface areas of assigned chains in a complex and unbound partner. The final step is to select mutations. We provide three options to allow users to do large-scale mutational scanning ( Figure S9 ).
An option ''Upload file'' allows to submit a list of mutations specified in the uploaded file
The ''alanine scanning'' option allows to perform alanine scanning for all contact residues between interaction partners. Contact residues here are defined as those with inter-atomic distances less than 6 Å between any heavy atom of interaction partners. MutaBind2 provides the contact residues list for download Contact residues are shown in orange in the residue list of ''Specify One or More Mutations,'' which allows to view contact residues in the 3D structure
For each mutation on a protein-protein complex, the MutaBind2 server provides the following results:
-DDG (kcal mol À1 ): predicted change in binding affinity induced by mutations (positive and negative signs correspond to mutations decreasing and increasing binding affinity, respectively) -The location on interface (yes/no): indicating whether the residue is located on a protein-protein interface in the case when a residue's solvent accessibility in the complex is lower than in the corresponding unbound partners As one mutation/interaction could be mapped to several Protein DataBank structures, the maximum predicted value of each method was used for each interaction-disruptive mutation and the minimum predicted values were used for those mutations that do not disrupt interactions. More details are shown in Figure S5 .
-Coordinates of the minimized mutant structure -Deleterious (yes/no), a mutation is classified as deleterious if DDG R 1.5 or DDG % À1.5 kcal mol À1 -The contribution of each term of the target function for every mutation -Homologous binding sites: the Inferred Biomolecular Interactions Server (Shoemaker et al., 2012 ) is used to identify the binding sites in protein-protein complexes homologous to the query Limitation of the Study 1. Requirement of the 3D structure of a protein-protein complex. Six features out of seven in our model are calculated using 3D structure of a protein-protein complex, which limits the application to those mutations that could not be mapped to the structural complex.
2. Multiple mutations instances with more than 10 mutations. As the number of multiple mutations with more than 10 mutations is small in our training dataset and prediction accuracy for these multiple mutations is low, the upper limit of 10 mutations was used in the study. Therefore, our model cannot be applied to the multiple mutation instances with more than 10 mutations.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. 
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a. Test on 1748
b. Test on S4191 c. Figure S7 . Pearson correlation coefficients between predicted and experimental ΔΔG for (a) mutations from S1748 test set located on interface and non-interface predicted by different methods. MutaBind2 here is trained on the dataset of "Skempi+Reverse"; (b) mutations from S4191 test set located on interface and non-interface predicted by MutaBind2(CV4) and MutaBind2(CV5). (c) The number of interfacial and non-interfacial mutations for two sets. Only statistically significant correlation coefficients (p-value < 0.01, calculated by one-sample t-test) are shown, Related to Table 1 and Figure 2 .
Category # of mutations
S1748 S4191
Interface 1221 3240 Non-interface 527 951 Figure S8 . Salt bridges were disrupted after Lys was mutated to Glu in Cationic Trypsin / Pancreatic Trypsin Inhibitor complex (PDB code: 2FTL). The experimental and predicted binding affinity change by MutaBind2 is 9.31 and 9.21 kcal mol -1 respectively, Related to Figure 2 . (PDB ID: 2FTL, 3HFM, 1PPF , 1BRS, 3QHY, 1DQJ and 1B41) in the 5% outlier, and the reason for showing these seven complexes is that they have more mutations (more than five mutations) included in the 5% outlier. (c) True positive rate (d) Mutations from a complex of bovine pancreatic trypsin inhibitor and bovine β-trypsin included in 1% outlier. (e) The number of mutations in categories of interface, non-interface and different types of protein complexes, Related to Figure 2 . Table S1 . Experimental datasets used for training and testing different methods, Related to Figure 1, Figure 2 , Table 1 , Table 2 and Table 3 . Compiled from SKEMPI2 M1707 M1337 plus reverse mutations; training dataset of MutaBind2 multiple mutation model S33, S19 and S487 datasets were obtained from https://github.com/haddocking/iSee. Protein complexes with more than 10 single mutations with experimental values of binding affinity changes from "Skempi" were used to build its reverse mutation set. .   Table S2 . The importance of each feature for MutaBind2 single and multiple mutation models, respectively. IncNodePurity is used for describing the importance which is the total decrease in node impurities from splitting on the variable, averaged over all trees, Related to Figure 1, Figure 2 , Table 1, Table 2 and Table 3 .
Dataset Description
Dataset
Model
Feature Importance All presented values of correlation coefficients are statistically significantly different from zero (p-value < 0.01) except for a p-value = 0.08 and b p-value = 0.32. * show statistically significant difference with p-value < 0.05 compared to MutaBind2 (Hittner2003 test implemented in R package cocor is used for comparing correlation coefficients (Diedenhofen and Musch, 2015; Hittner et al., 2003) ). The majority mutations in S33 and S19 are mutations decreasing binding affinity with experimentally measured ∆∆ #$% ≥ -0.38 and -0.24 kcal mol -1 , respectively. The ∆∆ values for mCSM-PPI2 trained and tested on S4169 (forward mutation dataset for parameterizing mCSM-PPI2 method) were obtained from http://biosig.unimelb.edu.au/mcsm ppi2/. ∆∆ values for mCSM-PPI2 trained and tested on S8338 (training dataset of mCSM-PPI2 method) were not provided on mCSM-PPI2 website, and the R and RMSE values for CV4 and CV5 were obtained from paper . S4191/S3310: MutaBind2 trained on S4191 and tested on S3310. S4169/S4169: MutaBind2 retrained on S4169 and tested on S4169. S8338/S8338: CV4 and CV5 validation for MutaBind2 retrained on S8338 and tested on S8338 .   Table S7 . Performance of MutaBind2 parameterized on different datasets where the reverse mutation dataset was compiled using complexes with a different number of mutations binned from 5 to 100. Related to Table 1  and Table 2. a. Performance of MutaBind2 retrained on "S3310+Reverse" set and tested on independent datasets of S487 and S877. 265 Protein-protein complexes in S3310 with the number of ∆∆ #$% > 0 mutations binned from 5 to 30, 10 to 30, 15 to 30, 10 to 50 and 10 to 100 were used for building the reverse mutation dataset. All: with every single forward mutation in S3310 being reversed. (The distribution of the number of ∆∆G EFG > 0 mutations over protein complexes is shown in Figure S1b ).
Methods
Cutoff
Dataset Cutoff R RMSE S487
10 to 30 0.41 1.25 5 to 30 0.39** 1.28 15 to 30 0.42* 1.23 10 to 50 0.41 1.26 10 to 100 0.40 1.26 All 0.36** 1.31 S877 10 to 30 0.55 1.37 5 to 30 0.54* 1.38 15 to 30 0.55 1.37 10 to 50 0.55 1.37 10 to 100 0.54 1.38 All 0.53** 1.40 * show statistically significant difference with p-value < 0.05 and **p-value < 0.01 compared to MutaBind2 trained on S4191 set where reverse mutation dataset was compiled using the cutoff of "10 to 30". For testing on S487 set, MutaBind2 was retrained after removing S487 from the training dataset.
b. Performance of MutaBind2 retrained on "Skempi+Reverse" set and tested on the independent dataset of S1748. The protein-protein complexes in Skempi with the number of ∆∆ #$% > 0 mutations binned from 5 to 30, 10 to 30, 15 to 30, 10 to 50 and 10 to 100 were used for building the reverse mutation dataset. All: with every single forward mutation in Skempi being reversed. *p-value < 0.05 and **p-value < 0.01 compared to MutaBind2 using cutoff of "10 to 30" (Hittner2003 test). Table 2 and Figure 2 . In the dataset of S3310, there are 408 mutations with multiple experimental measurements of binding affinity changes and their standard deviations are all less than 1 kcal mol -1 (The distribution of standard deviation is shown in Figure  S1a ). S4191: the average values were used for these 408 mutations; S4944: using all experimental measurements of ∆∆ #$% for these 408 mutations; S4090: only mutations with standard deviations with less than or equal to 0.4 kcal mol -1 are included in the training set, and the average value was used for these cases; S4183: only mutations with the difference between maximal and minimal ∆∆ #$% values of less than 2 kcal mol -1 (the cutoff was used by mCSM-PPI2) are included in the training set, and the average value was used for these cases. All presented values of correlation coefficients are statistically significantly different from zero (p-value << 0.01).
Cutoff
All mutations
The leave-one-complex-out validation results
Training/Test
All mutations
Transparent Methods
Experimental datasets of mutations used for training
The training dataset is compiled from the most recent SKEMPI2.0 database (Jankauskaite et al., 2019) , which includes experimentally measured values of dissociation constants for wild-type and mutant proteins with the available crystal structures. Changes in binding affinity are also provided in SKEMPI2.0 and calculated as ∆ = ( N ). We applied the following criteria to the SKEMPI2.0 data set by removing the following complexes and mutations: (a) complexes with modified residues at the protein-protein binding interface; (b) complexes containing a chain of less than 20 residues long; (c) mutations with mutated sites having missing coordinates; (d) changes in affinity measured by an 'unusual method' as defined in SKEMPI2.0; (e) mutations on metal coordination sites; (f) mutations without binding affinity experimental values; and (g) entries with ten or more multiple mutations ( Figure S1 ). There are 408 mutations with multiple experimental measurements of changes in binding affinity and their standard deviations are all less than 1.0 kcal mol -1 ( Figure S1a) , and the average value was used for these cases. Three additional ways to process these cases were tried but the performance did not change (Table S10 ). As the number of multiple mutations with more than 10 mutations is small and prediction accuracy for these multiple mutations is low (Table S11), the upper limit of 10 mutations was used in the study. As a result, 3,310 single mutations from 265 wild-type proteinprotein complexes (it will be referred to as S3310) and 1,337 multiple mutations from 120 wild-type protein-protein complexes (it will be referred to as M1337) were retained (Table S1 and Figure S2 ). Multiple mutations correspond to cases where several mutations are introduced on one or several chains of a protein complex simultaneously.
The Gibbs free energy (∆∆ ) of a system can be represented as a thermodynamic state function where the absolute values of ∆∆ for a forward mutation (∆∆ 8)→@() ) and ∆∆ for the reverse mutation (∆∆ @()→8) ) should be approximately equal to each other. In order to prepare a more balanced training dataset, we augmented the existing mutations increasing binding affinity from the forward mutation sets with the modelled reverse mutations (see Table  S1 ). In order to balance the prediction accuracy for both types of mutations: decreasing and increasing binding affinity, we used protein complexes with the number of experimentally characterized mutations from 10 to 30 and 10 to 50 to build the single and multiple reverse mutation dataset respectively. The performance is shown in Table S7 . Therefore, the final training set including both forward and reverse mutations comprised 4,191 single mutations from 265 wildtype protein complexes (it will be referred to as S4191) and 1,707 multiple mutations from 120 wild-type protein complexes (it will be referred to as M1707), respectively (Table S1 ).
Structure optimization protocol
For the forward mutation datasets S3310 and M1337 (∆∆ 8)→@() ), the structure optimization protocol was the same as the one used in MutaBind (the flowchart for the structure optimization protocol is shown in Figure S3 ). Namely, we used the BuildModel module of FoldX (Guerois et al., 2002) to introduce single or multiple point mutations on the wild-type crystal structure obtained from the Protein Data Bank (PDB) (Berman et al., 2000) . Next we added missing heavy side-chain and hydrogen atoms via the VMD program (Humphrey et al., 1996) using the topology parameters of the CHARMM36 force field (MacKerell et al., 1998) . After that we performed a 100-step energy minimization in the gas phase for both wild-type and mutant complex structures applying harmonic restraints with the force constant of 5 kcal mol -1 Å -2 on the backbone atoms of all residues. The energy minimization was carried out by NAMD program version 2.9 (Phillips et al., 2005) using the force field CHARMM36 (MacKerell et al., 1998) . A 12 Å cutoff distance for nonbonded interactions was applied to the systems. Lengths of hydrogen-containing bonds were constrained by the SHAKE algorithm (Hoover, 1985) .
For the reverse mutation datasets, we modeled the mutant structures with the Modeller software (Sali and Blundell, 1993) using wild-type crystal structures as the templates (Table S8 ). To minimize the error introduced by structural modelling, only the mutated protein chain was modeled for single mutations, and for multiple mutations on multiple protein chains, the whole complex was modelled. The structural model was discarded if the root-mean-square deviation of all aligned Cα atoms between any of the modelled chains and the template was larger than 2 Å. Then the RepairPDB module was applied to further optimize the structure and mutations were introduced using the BuildModel module from FoldX. After that a 1000-step energy minimization in the gas phase was carried out for both wild-type and mutants using harmonic restraints (with the force constant of 5 kcal mol -1 Å -2 ) applied on backbone atoms of all residues using NAMD. Minimization was performed for the whole protein complex.
Calculating changes in binding affinity
The scoring function of MutaBind2 includes seven distinct terms for single and multiple mutations, it is parameterized using the S4191 and M1707 datasets (Table S1 ), respectively. The terms that contribute significantly to the quality of the MutaBind2 single and multiple mutation models are shown in Table S2 and described below.
The six terms of the scoring function described below are common for both single and multiple mutation models.
• ∆∆ 7.8 is the change of van der Waals interaction energy upon a single or multiple mutation(s) (∆∆ 7.8 = ∆ 7.8 @() − ∆ 7.8 8) ). ∆ 7.8 is calculated as a difference between van der Waals energies of a complex and each interacting partner using the ENERGY module of CHARMM (Brooks et al., 1983) . The minimized structure of the wild-type or mutant complex structure was used for the calculation.
• ∆∆ 9:;7 approximates the change of polar solvation energy upon mutation(s) (∆∆ 9:;7 = ∆ 9:;7 @() − ∆ 9:;7 8) ), ∆ 9:;7 is obtained from numerically solving the Poisson-Boltzmann (PB) equation with the PBEQ module (Im et al., 1998) of the CHARMM program using the minimized structure of the wild-type or mutant complex. For the PB calculation, dielectric constants ε = 2 for the protein interior and ε = 80 for the exterior aqueous environment were used. • ∆∆ <:;. is the change in stability of the protein complex upon mutation(s) (∆∆ <:;. = ∆ <:;. @() − ∆ <:;. 8) ) where each term is defined as the unfolding free energy of the mutant and wild-type protein complexes. It is calculated with the BuildModel module from the FoldX software (Guerois et al., 2002) which uses an empirical force field. This term may account for those cases where mutated proteins are unfolded in unbound states and can only fold upon binding to its partner. • %*A) 8) and ?:@ 8) are solvent accessible surface areas of the mutated residues in the wild type unbound partner and complex structure respectively. These terms are calculated by the DSSP program (Joosten et al., 2011) using the crystal structure of the wild-type complex. For multiple mutations this term is calculated as a sum of the solvent accessible surface areas of all mutated residues.
• is the change of evolutionary conservation of a mutated site upon introducing mutations calculated using the PROVEAN program (Choi et al., 2012) . This is used to account for the fact that a site can be evolutionary conserved because it is important for interactions with other proteins and any change in this site may affect its function in a detrimental way. For multiple mutations this term is calculated by summing up CS for all mutations.
A scoring function for single mutations included an additional term, ?:-) 8) , representing the number of interactive residues between one partner where a mutation was introduced and another partner in a wild type structure. If any heavy atom of a residue in one partner was located within 10 Å from any heavy atom of another partner, we defined this residue as an interactive residue. A scoring function for multiple mutations included an additional term ∆ 7.8 8) calculated as a difference between van der Waals energies of a complex and each interacting partner for the wild-type structure, as described above.
MutaBind2 predictive models were built using the random forest (RF) regression algorithm implemented in the R package "randomForest" using Breiman's random forest algorithm (Breiman, 2001) . Hyperparameter optimization in a balanced "CV2" cross-validation (see the section below) suggested that the number of trees "ntree" parameter should be set to 500 and the number of features/terms randomly sampled as candidates for splitting at each node ("mtry") should be set to 2. Feature importance in RF models is shown in Supplementary Table 2 and all features listed above contribute significantly to the quality of the models. The performance of MutaBind2 trained on S4191 and M1707 sets is shown in Table S3 and Figure S4c . The Pearson correlation coefficient between experimental and calculated changes in binding affinity is R = 0.82 and the corresponding root-mean-square error (RMSE) is 1.19 kcal mol -1 for single mutations and R = 0.87 and the RMSE is 1.61 kcal mol -1 for multiple mutations. We also tested the performance of other algorithms, including Support Vector Machine (SVM) and eXtreme Gradient Boosting (XGBoost), however, the random forest regression algorithm shows the best performance (Table S4) .
MutaBind2 calculations take several minutes for a single mutation in a protein complex of about 350 residues, and require less than a minute for each additional mutation introduced in the same complex and therefore require about 12 hours for calculations of one thousand mutations ( Figure S10 ).
Five types of cross-validation (CV) procedures
We performed five types of cross-validation. In the "CV1" cross-validation, 80% of all mutations from S4191 or M1707 set were randomly selected to train the model and the remaining 20% of the mutations were used for testing; we repeated the procedure 100 times. For "CV2" cross-validation, 50% of the mutations were randomly chosen for training and the remaining mutations for testing, also repeated 100 times. As shown in Figure S2 , the distribution of the number of mutations per protein is not uniform, so to take this bias into account, we performed the third type of cross-validation ("CV3"). First, we randomly sampled up to ten mutations per protein complex from S4191 and M1707, the procedure was repeated 10 times and yielded ten subsets. Then 80 percent of the mutations were randomly selected from each subset for training and the rest for testing, repeated 10 times.
We also performed the "CV4" cross-validation by leaving one complex and its mutations out as a test set and using the rest of the complexes/mutations to train the model, repeating this process for each protein complex. In addition, a "CV5" cross-validation accounted for similarities between binding sites of different complexes (the definition of similar binding sites is taken from (Jankauskaite et al., 2019; Moal and Fernandez-Recio, 2012) ). Namely, we used all complexes and corresponding mutations from one cluster/type of binding site for testing and trained the model on the rest of the complexes/mutations, repeated for each type of binding site. During the cross-validation procedures, forward and reverse mutations were kept in the same set, either training or testing.
Assessment of quality of classification
One way to evaluate the performance of MutaBind2 is to assess the quality of classification of mutations into mutations with large amplitudes of their effects on binding affinity: highly decreasing (∆∆ ≥ 1.5 kcal mol -1 ) and highly increasing (∆∆ ≤ -1.5 kcal mol -1 ). The explanation is provided in Figure S6c and Figure S6d .
Prediction performance was measured using area under the ROC curve (AUC), accuracy, precision, sensitivity, specificity, negative predictive value (NPV) and Matthews correlation coefficient (MCC). Positives and negatives were defined as those mutations with predicted ∆∆ values within or outside the range specified above for experimental ∆∆ values. The accuracy was defined as a percentage of correctly classified mutations (true positives, TP, and true negatives, TN) out of the total number of mutations (TP + TN)/(TP + TN + FP + FN), where FN are false negatives, and FP are false positives. Sensitivity was defined as TP/(TP + FN), specificity was calculated as TN/(TN + FP) (false negatives, FN and false positives, FP). Additionally, in order to account for imbalances in the labeled dataset, the quality of the predictions was described by the Matthews correlation coefficient (MCC), a performance measure which is known to be more robust on unbalanced datasets:
